Key Features
- Combination peptide blend targeting growth hormone axis in preclinical research
-  CJC‑1295 (No DAC) stimulates GH release via GHRH receptor activation
- Ipamorelin selectively activates ghrelin receptor to potentiate GH secretion
- Used in studies investigating pituitary and hypothalamic interactions
- Â Stable, lyophilised powder suitable for laboratory research
Specifications
- Form: Lyophilised peptide powder
- Purity: ≥ 99%
- Verification: Confirmed by HPLC and Mass Spectrometry; batch-specific CoA available
- Manufacturing: Produced under controlled lab conditions
Storage Conditions
- Unreconstituted: −20 °C
- Reconstituted (bacteriostatic water): 2–8 °C
- Avoid repeated freeze-thaw; protect from light
Research Use Only Disclaimer
- For laboratory research purposes only
- Not for human consumption
- Not for medical, veterinary, or diagnostic use
- Â Must be handled by qualified professionals
Additional Information
- CAS Numbers: 863288‑34‑0 (CJC‑1295 No DAC) / 170851‑70‑4 (Ipamorelin)
- Â Molecular Formulas: C152H252N44O42 / C38H49N9O5



